ANAB vs. ALBO, RNA, TGTX, ACAD, GPCR, INDV, RYTM, JANX, GERN, and BHC
Should you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include Albireo Pharma (ALBO), Avidity Biosciences (RNA), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Structure Therapeutics (GPCR), Indivior (INDV), Rhythm Pharmaceuticals (RYTM), Janux Therapeutics (JANX), Geron (GERN), and Bausch Health Companies (BHC). These companies are all part of the "pharmaceutical preparations" industry.
AnaptysBio (NASDAQ:ANAB) and Albireo Pharma (NASDAQ:ALBO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.
AnaptysBio received 53 more outperform votes than Albireo Pharma when rated by MarketBeat users. Likewise, 65.61% of users gave AnaptysBio an outperform vote while only 56.55% of users gave Albireo Pharma an outperform vote.
Albireo Pharma has a net margin of -228.51% compared to AnaptysBio's net margin of -711.17%. Albireo Pharma's return on equity of -97.13% beat AnaptysBio's return on equity.
AnaptysBio currently has a consensus target price of $46.38, suggesting a potential upside of 97.93%. Given AnaptysBio's higher probable upside, equities research analysts plainly believe AnaptysBio is more favorable than Albireo Pharma.
In the previous week, Albireo Pharma's average media sentiment score of 0.20 beat AnaptysBio's score of 0.00 indicating that Albireo Pharma is being referred to more favorably in the news media.
94.3% of Albireo Pharma shares are held by institutional investors. 33.7% of AnaptysBio shares are held by company insiders. Comparatively, 6.9% of Albireo Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
AnaptysBio has a beta of -0.33, suggesting that its stock price is 133% less volatile than the S&P 500. Comparatively, Albireo Pharma has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.
Albireo Pharma has higher revenue and earnings than AnaptysBio. Albireo Pharma is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.
Summary
AnaptysBio beats Albireo Pharma on 9 of the 16 factors compared between the two stocks.
Get AnaptysBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AnaptysBio Competitors List
Related Companies and Tools
